...CR rate of 18% in a clinical trial. Data from the nadofaragene trial, conducted by FKD Therapies Oy...
...will assume exclusive, worldwide rights to the compound from FKD upon approval of a BLA. FKD...

...FKD Therapies Oy last year for an undisclosed sum. Nadofaragene originated from Merck & Co. Inc. (NYSE:MRK); FKD...
...high levels of the naturally occurring antitumor protein. Elizabeth S. Eaton, Staff Writer Blackstone Life Sciences Ferring Pharmaceuticals A/S FKD Therapies Oy interferon...

...Phase III data is expected in 2019, according to Ferring EVP and CMO Klaus Dugi. FKD...
...BCG therapy. FKD Therapies Oy, Kuopio, Finland Ferring Pharmaceuticals A/S, Saint-Prex, Switzerland Business: Cancer Jennie Walters Instiladrin, rAd-IFN Ferring Pharmaceuticals A/S FKD Therapies Oy...

...Phase III data is expected in 2019, according to Ferring EVP and CMO Klaus Dugi. FKD...
...Fast Track designations to treat NMIBC in patients unresponsive to BCG therapy. Jennie Walters Instiladrin, rAd-IFN Ferring Pharmaceuticals A/S FKD Therapies Oy Interferon Merck...

...Merck granted newco FKD exclusive rights to a gene therapy cancer candidate in exchange for an...
...to a gene therapy cancer candidate in exchange for an equity stake. Founded in February, FKD...
...The newco plans to begin Phase II testing in superficial bladder cancer next half. FKD...

...Merck & Co. Inc (NYSE:MRK) granted newco FKD Therapies Oy (Kuopio, Finland) exclusive rights to a gene therapy...
...to a gene therapy cancer candidate in exchange for an equity stake. Founded in February, FKD...
...rAd-IFN). The newco plans to begin Phase II testing in superficial bladder cancer next half. FKD...